Loading clinical trials...
Loading clinical trials...
An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
Conditions
Interventions
Tesetaxel
Tesetaxel
+2 more
Locations
3
United States
START Midwest
Grand Rapids, Michigan, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Start Date
March 6, 2020
Primary Completion Date
September 30, 2020
Completion Date
June 15, 2021
Last Updated
July 28, 2021
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Odonate Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions